Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MIF | P14174 | 4/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15460411 | 0.83 | PTPN1 (0.45) | PTPN1MAOBMIFMAPTHSD17B10 | |
| SCHEMBL15460398 | 0.81 | PTPN1 (0.43) | PTPN1MAOBMIFS1PR1MAPT | |
| SCHEMBL16602594 | 0.81 | DRD2 (0.37) | PTPN1MAOBMIFS1PR1 | |
| SCHEMBL12687453 | 0.78 | S1PR1 (0.48) | PTPN1MIFS1PR1MAPTLMNA | |
| SCHEMBL15460491 | 0.77 | HDAC1 (0.46) | MAPTLMNAKDM4EHSD17B10MAPK1 | |
| SCHEMBL15460492 | 0.76 | HDAC1 (0.47) | MAPTLMNAKDM4EHSD17B10MAPK1 | |
| SCHEMBL15460499 | 0.76 | HDAC1 (0.49) | MAPTLMNAKDM4EHSD17B10MAPK1 | |
| SCHEMBL15460506 | 0.76 | HDAC1 (0.46) | MAPTLMNAKDM4EHSD17B10MAPK1 | |
| SCHEMBL15460497 | 0.76 | HDAC1 (0.43) | MAPTKDM4EHSD17B10MAPK1SMN1; SMN2 | |
| SCHEMBL15460505 | 0.76 | HDAC1 (0.49) | MAPTLMNAKDM4EHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921552-B2 | Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-30 | — | — | US | disclosed |
| US-20140039190-A1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039190-A1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | TP53, MCL1, SDHA | PTPN1 4424/4885MAOB 1683/4885MIF 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.